Следене
Zhili Zheng
Zhili Zheng
National Cancer Institute
Потвърден имейл адрес: mail.nih.gov
Заглавие
Позовавания
Позовавания
Година
Cancer regression in patients after transfer of genetically engineered lymphocytes
RA Morgan, ME Dudley, JR Wunderlich, MS Hughes, JC Yang, ...
Science 314 (5796), 126-129, 2006
41232006
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy
RA Morgan, N Chinnasamy, D Abate-Daga, A Gros, PF Robbins, Z Zheng, ...
Journal of immunotherapy 36 (2), 133-151, 2013
12852013
T-cell transfer therapy targeting mutant KRAS in cancer
E Tran, PF Robbins, YC Lu, TD Prickett, JJ Gartner, L Jia, A Pasetto, ...
New England Journal of Medicine 375 (23), 2255-2262, 2016
12612016
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
N Zacharakis, H Chinnasamy, M Black, H Xu, YC Lu, Z Zheng, A Pasetto, ...
Nature medicine 24 (6), 724-730, 2018
7822018
Immunogenicity of somatic mutations in human gastrointestinal cancers
E Tran, M Ahmadzadeh, YC Lu, A Gros, S Turcotte, PF Robbins, ...
Science 350 (6266), 1387-1390, 2015
7542015
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability
CJ Cohen, Y Zhao, Z Zheng, SA Rosenberg, RA Morgan
Cancer research 66 (17), 8878-8886, 2006
5812006
Transformation by Wnt family proteins correlates with regulation of beta-catenin.
H Shimizu, MA Julius, M Giarre, Z Zheng, AM Brown, J Kitajewski
Cell growth & differentiation: the molecular biology journal of the American …, 1997
5631997
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions
PF Robbins, YF Li, M El-Gamil, Y Zhao, JA Wargo, Z Zheng, H Xu, ...
The Journal of Immunology 180 (9), 6116-6131, 2008
4132008
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity
Y Zhao, QJ Wang, S Yang, JN Kochenderfer, Z Zheng, X Zhong, ...
The Journal of Immunology 183 (9), 5563-5574, 2009
4122009
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma
L Zhang, RA Morgan, JD Beane, Z Zheng, ME Dudley, SH Kassim, ...
Clinical cancer research 21 (10), 2278-2288, 2015
3832015
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation
Y Zhao, Z Zheng, CJ Cohen, L Gattinoni, DC Palmer, NP Restifo, ...
Molecular therapy 13 (1), 151-159, 2006
3582006
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma
RA Morgan, LA Johnson, JL Davis, Z Zheng, KD Woolard, EA Reap, ...
Human gene therapy 23 (10), 1043-1053, 2012
3432012
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment
L Zhang, SP Kerkar, Z Yu, Z Zheng, S Yang, NP Restifo, SA Rosenberg, ...
Molecular therapy 19 (4), 751-759, 2011
3152011
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of …
RA Morgan, ME Dudley, YYL Yu, Z Zheng, PF Robbins, MR Theoret, ...
The Journal of Immunology 171 (6), 3287-3295, 2003
3052003
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions
MS Hughes, YYL Yu, ME Dudley, Z Zheng, PF Robbins, Y Li, ...
Human gene therapy 16 (4), 457-472, 2005
2942005
Pilot trial of adoptive transfer of chimeric antigen receptor–transduced T cells targeting EGFRvIII in patients with glioblastoma
SL Goff, RA Morgan, JC Yang, RM Sherry, PF Robbins, NP Restifo, ...
Journal of immunotherapy 42 (4), 126-135, 2019
2822019
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines
Y Zhao, Z Zheng, PF Robbins, HT Khong, SA Rosenberg, RA Morgan
The Journal of Immunology 174 (7), 4415-4423, 2005
2662005
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines
Y Zhao, AD Bennett, Z Zheng, QJ Wang, PF Robbins, LYL Yu, Y Li, ...
The Journal of Immunology 179 (9), 5845-5854, 2007
2632007
Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen MAGE-A3
YC Lu, LL Parker, T Lu, Z Zheng, MA Toomey, DE White, X Yao, YF Li, ...
Journal of Clinical Oncology 35 (29), 3322, 2017
2532017
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition
S Yang, CJ Cohen, PD Peng, Y Zhao, L Cassard, Z Yu, Z Zheng, S Jones, ...
Gene therapy 15 (21), 1411-1423, 2008
2232008
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20